Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Romidepsin - Celgene Corporation

Next Previous
X
Search
Drug Profile

Romidepsin - Celgene Corporation

Alternative Names: Depsipeptide; FK 228; FR 901228; Istodax; NSC 630176; NSC 630176D; RMD

Latest Information Update: 15 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Developer Canadian Cancer Trials Group; Celgene Corporation; Columbia University; Lymphoma Academic Research Organisation; University of Birmingham; University of California at San Francisco; University of Kansas Medical Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytostatic antibiotics; Depsipeptides; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T-cell lymphoma
  • Registered Peripheral T-cell lymphoma
  • Phase I/II Lymphoid leukaemia; Multiple myeloma; T-cell leukaemia; T-cell lymphoma; Triple negative breast cancer
  • No development reported Diffuse large B cell lymphoma; Haematological malignancies
  • Discontinued Pancreatic cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 14 Dec 2023 Seagen has been acquired by Pfizer
  • 01 Nov 2023 Celgene completes a phase I/II trial in Multiple myeloma (Combination therapy, Second-line or greater) in the USA (IV) (NCT01755975)
  • 13 Dec 2022 The Lymphoma Academic Research Organisation completes a phase III trial for Peripheral T-cell lymphoma (First line therapy, Combination therapy)in Belgium, France, Germany, Italy, South Korea, Portugal, Singapore and Spain (IV, Infusion) (NCT01796002)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top